FMP
Akouos, Inc.
AKUS
NASDAQ
Inactive Equity
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.
13.29 USD
0 (0%)
AKUS Financial Statements
Year
2021
2020
2019
2018
CF from Operating Activities
-63.73M
-40.77M
-19.51M
-6.74M
Net Income
-86.67M
-48.6M
-25.74M
-6.01M
Depreciation & Amortization
3.75M
2.17M
697k
55k
Deferred Income Taxes
0
0
0
0
Stock Based Compensation
9.48M
4.5M
138k
22k
Change in Working Capital
7.99M
882k
3.14M
241k
Accounts Receivable
0
0
0
0
Inventory
0
0
0
0
Accounts Payable
385k
583k
-76k
74k
Other Working Capital
7.61M
299k
3.21M
167k
Other Non-Cash Items
1.72M
281k
2.26M
-1.04M
CF from Investing Activities
117.62M
-243.88M
-3.44M
-532k
Investments in Property, Plant & Equipment
-9.02M
-4.53M
-3.44M
-532k
Net Acquisitions
0
0
0
0
Investment Purchases
-161.36M
-268.85M
0
0
Sales/Maturities of Investments
288M
29.5M
0
0
Other Investing Activites
0
0
0
0
CF from Financing Activities
217k
328.5M
25M
24.85M
Debt Repayment
-378k
-253k
-99k
-22k
Common Stock Issued
406k
227.27M
0
0
Common Stock Repurchased
35k
0
0
-110k
Dividends Paid
0
0
0
0
Other Financing Activites
217k
328.5M
25M
24.85M
Free Cash Flow
-72.75M
-45.3M
-22.95M
-7.27M
Operating Cash Flow
-63.73M
-40.77M
-19.51M
-6.74M
Capital Expenditures
-9.02M
-4.53M
-3.44M
-532k
Cash at Beginning of Period
70.25M
26.39M
24.34M
6.76M
Cash at End of Period
124.36M
70.25M
26.39M
24.34M
Net Change In Cash
54.11M
43.85M
2.06M
17.58M
Retained Earning Schedule
Year
2021
2020
2019
Retained Earnings (Previous Year)
-81.72M
-33.12M
-7.38M
Net Income
-86.67M
-48.6M
-25.74M
Stock Repurchases
35k
0
0
Dividend Paid
0
0
0
Retained Earnings
-168.4M
-81.72M
-33.12M
Other Distributions
-86.64M
-48.6M
-25.74M
PPE Schedule
Year
2021
2020
2019
Gross PPE
40.14M
21.35M
0
Annual Depreciation
3.75M
2.17M
697k
Capital Expenditure
-9.02M
-4.53M
-3.44M
Net PPE
45.42M
23.71M
2.74M
Intangible and Goodwill Schedule
Year
2021
2020
2019
Acquisitions and Adjustments
0
0
0
Goodwill (Previous Year)
0
0
0
Goodwill
0
0
0
All figures are in USD.
